Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) EBITDA Margin (2023 - 2025)

NewAmsterdam Pharma's EBITDA Margin history spans 3 years, with the latest figure at 233656.25% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 23293489.0% year-over-year to 233656.25%; the TTM value through Dec 2025 reached 904.29%, down 37414.0%, while the annual FY2025 figure was 904.29%, 37414.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 233656.25% at NewAmsterdam Pharma, down from 20601.15% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 57.18% in Q3 2024 and bottomed at 233656.25% in Q4 2025.
  • The 3-year median for EBITDA Margin is 1657.1% (2023), against an average of 22945.29%.
  • The largest annual shift saw EBITDA Margin skyrocketed 544240bps in 2024 before it tumbled -23293489bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 6163.76% in 2023, then surged by 88bps to 721.36% in 2024, then plummeted by -32291bps to 233656.25% in 2025.
  • Per Business Quant, the three most recent readings for NAMS's EBITDA Margin are 233656.25% (Q4 2025), 20601.15% (Q3 2025), and 91.26% (Q2 2025).